Financing channel feed – Endpoints News

Financing channel feed

Medicxi kickstarts a new cancer drug developer with $19M launch round

8 years ago

Shooting for PhIII, Spero tees up a new lead antibiotic in-licensed cheap as it lines up $86M IPO

8 years ago

Deerfield commits $50M-plus to translational drug R&D at the Broad

8 years ago

Abbas Hussain swings from top GSK pharma post to powerhouse Chinese private equity player C-Bridge

8 years ago

Third Rock-backed Allena looks to springboard a $92M IPO off of a failed PhIIb

8 years ago

Third Rock, SV bankroll another PhI/II for a new, improved and jab-free wet AMD drug

8 years ago

Facebook billionaires Peter Thiel and Sean Parker backing a stealth immunotherapy biotech — report

8 years ago

Armed with a $47M round, Gates-backed Visterra aims at a PhIIb flu drug study

8 years ago

Rhythm Pharma IPO goes over the top, snags $120M in latest sign the biotech window is wide open

8 years ago

Backed by Big Pharma VCs, Palleon ramps up a new approach to immuno-oncology with a $48M startup round

8 years ago

Amgen-partnered Immatics bags a $58M round to fund its first clinical steps on new T-cell tech for cancer

8 years ago

Top scientists and BD execs craft Cullinan, a $150 million R&D portfolio shop focused on cancer

8 years ago

Genzyme vet David Meeker takes helm at stealthy KSQ with $76M and a new map for drug discovery

8 years ago

Next-gen CAR-T, TCR player Autolus gains $80M for clinical trial work

8 years ago

Two young scientists bag $20M to perfect their CRISPR attack on disease-causing bacteria at upstart Eligo

8 years ago

Pfizer spins off drug orphans into a PhIII-ready startup backed by Bain to the tune of $103M

8 years ago

OrbiMed, RA Capital back a $26M raise for Realm’s two mid-stage drugs

8 years ago

A China biotech unicorn scores big with $150M-plus IPO on Nasdaq, stock rockets up

8 years ago

Chris Garabedian's Xontogeny shepherds its first biotech through a $10M startup round

8 years ago

Lightstone crew adds a $250M Fund II with plans to back biotech startups

8 years ago

From big biopharma to biotech CEO, John Houston’s R&D journey highlights a fast-changing world

8 years ago

Atlas ramps up a new biotech player focused on neurology, with a $30M round to fund the work

8 years ago

Ex-GSK CEO, R&D chief Andrew Witty and Moncef Slaoui are jumping into the biotech VC game

8 years ago

Harvard biotech wiz Greg Verdine grabs a $55M A round to build a groundbreaking biotech

8 years ago

First page Previous page 136 137 138139140 141 142 Next page Last page